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Objective: The aim was to critically evaluate well-established regulatory agencies mAb
biosimilar guidelines for development and marketing authorization about quality, efficacy
and safety and compare to BRICS-TM regulations to identify challenges.
Materials and Methods: The current valid guidelines of EMA, WHO, USFDA,
BGTD/HC, ICH, and BRICS-TM were obtained from official websites and comparative
qualitative review was performed.
Results: The review revealed that Health Canada uses mAb specific guidelines
from EMA or USFDA when necessary. The BRICS agencies (except Russia) have
incorporated some or most of the WHO SBP TRS and related annexes in similar
national biotechnological/biological guidelines; however, gaps or insufficient information
have been identified. The Russian Federation has issued general product registration
guideline/s with very brief information about mAbs. The TMMDA (Turkey) has published
an updated biosimilar guideline which parallels those of the EMA and the ones fromWHO;
however, no mAb specific guidelines are published. COFEPRIS (Mexico) has published a
biotechnological/biological product registration guideline with no information about mAb.
The SAHPRA biosimilar guideline has an annex on mAbs which focuses on non-clinical
and clinical aspects.
The comparative evaluation of BRICS-TM agencies indicates a gap pertaining to
clarification for physico-chemical characterization, manufacturing process, overages and
compatibility requirements between biological substances and excipients specifically on
mAbs. In vitro assay requirements seem quite aligned with those of WHO, whereas in vivo
studies mostly have disparity in terms of necessity, type of studies as well as design and
criteria. Clinical safety and efficacy studies are indicated in emerging regulatory agencies,
however detailed information pertaining to design, size of populations, requirements for
primary and secondary endpoints, clarity and evaluation criteria differ. In general, BRICS-
TM agencies allow extrapolation of indications provided that pre-defined conditions are
met. Interchangeability, switching and substitution of biosimilars are not defined in most
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of BRIC-TM guidelines whereas South Africa, by law, allows neither interchangeability
nor substitution. Pediatric research remains questionable across BRICS-TM.
Conclusions: EMA, USFDA guidelines are broadly aligned with WHO and in addition,
they also contain specific requirements pertaining to their own region. BRICS-TM
has considerably less defined mAb specific biosimilar development and comparability
parameters in their published guidelines.
Keywords: monoclonal antibody, biosimilar, regulatory, comparability, quality, manufacturing, non-clinical,
emerging markets
INTRODUCTION
Biosimilars are biotherapeutic products with identical quality
and similar safety and efficacy profiles as the reference biological
product. It is essential that the standard of evidence supporting
the decisions to grant marketing authorization for biosimilars be
sufficient to ensure that the products meet acceptable levels of
quality, safety and efficacy for public health purposes.
Biosimilars cover specific products such as low molecular
weight heparins, insulin, human follicular stimulating hormones,
interferon’s, erythropoietin, granulocyte stimulating factor,
monoclonal antibodies. Amongst all, the class of monoclonal
antibody (mAbs) products is getting higher importance due to
its use in chronic diseases like rheumatoid arthritis, cancers,
ulcerative colitis, Crohn’s disease etc. Monoclonal antibodies are
complex biotherapeutic proteins known as immunoglobulins (Ig)
and are derived from different technologies such as hybridoma,
recombinant DNA (rDNA), B lymphocyte immortalization etc.
To develop clinically equivalentmAb to prove comparability with
reference biological product raises multiple challenges starting
from reference product selection, characterization (physico-
chemical, manufacturing process, in vitro/vivo assays), clinical
safety and efficacy.
Although the European Medicines Agency (EMA), the
United States Food and Drug Administration (USFDA) and
the World Health Organization (WHO) have issued specific
guidelines with questions and answer documents clarifying
Abbreviations: ADCC, Antibody-Dependent Cell-Mediated Cytotoxicity;
ADCP, Antibody-Dependent Cellular-Phagocytosis; ANVISA, National Health
Surveillance Agency; AUC, Area Under Curve; AUEC, Area Under The Effect
Curve; BGTD, Biologics and Genetic Therapies Directorate; BRICS-TM, Brazil
Russia India China South Africa- Turkey Mexico; CDC, Complement Dependent
Cytotoxicity; CDE, Center of Drug Evaluation, CDR, Complementarity-
Determining Regions; CDSCO, Central Drug Standards Control Organization;
CFDA, China Food and Drug Administration; CHMP, Committee for Medicinal
Products for Human Use; COFEPRIS- Federal Commission for the Protection
Against Sanitary Risks; EEA, European Economic Area; EMA, European
Medicines Agency; Fc, fragment crystallizable; FcRn, neonatal Fc receptor; HC,
Health Canada; HED, human equivalent dose; mAbs, monoclonal antibodies;
MOA, Mechanism of Action; NRA, National Regulatory Authority; PMS,
Post Marketing Surveillance; PK, Pharmacokinetic; PREA, Pediatric Research
Equity Act; PSUR, Periodic Safety Update Reports; PV, Pharmacovigilance;
RBP, Reference Biologic Product; RMP, Risk Management Plan; ROA, Route of
Administration; SAHPRA, South African Health Products Regulatory Agency;
SBP, Similar Biologic Product; TK, Toxicokinetic; TSE, Transmissible Spongiform
Encephalopathy, USFDA, United States Food & Drug Administration, WHO,
World Health Organization.
doubts pertaining to development, many other agencies are yet
to develop mAb specific regulatory guidance. A few emerging
markets such as Brazil, Russia and Mexico have very brief
or unclear mAb/biosimilar guidelines. Indian and Chinese
guidelines are in line with those of the WHO, whereas those
of South Africa and Turkey are mostly aligned with the
EMA guidelines with minor differences. Supplementary Table 1
indicates list of authorized mAb biosimilars in each market
between 2013 and 2018. The information has been obtained
by online search on official websites and extracted from related
published articles.
In this review, we present quality, non-clinical and clinical
requirements for the development of biosimilar mAbs and
for their licensing by the EMA (overview of EMA guidelines
related to the development and approval of biosimilars) (Schiestl
et al., 2017), the WHO, USFDA, BGTD/HC, ANVISA/Brazil,
Russian Federation/Russia, CDSCO/India, CFDA/China,
SAHPRA/South Africa, TMMDA/Turkey, COFEPRIS/ Mexico.
We have referenced and interpreted general biosimilar guidelines
where guidelines specific to mAbs are unavailable. To get an
overall understanding, we have also reviewed and cross-referred
ICH guidelines (ICH, 1995a,b, 1997, 1999a,b,c, 2004a,b, 2012).
The biosimilar and reference product are defined using varied
terminologies by each agency. For ease of understanding, we
have followed agency specific terminologies for review and
comparison, throughout this article.
MATERIALS AND METHODS
The current and valid English-language guidelines including
published questions and answers such as the EMA guidelines
pertaining to biosimilar medicinal product and mAbs, technical
report series (TRS) and pertinent annexes of the WHO,
specifically for mAbs, guidance for industry from USFDA, the
guidance document and the Fact sheet issued by BGTD/HC,
MCC (currently known as SAHPRA) /South Africa guidance
document and guidelines on similar biologics from India which
were obtained from the official websites of the respective
regulatory agencies.
Non-English language guidelines such as resolution RDC
n◦ 55/2010 published by ANVISA, the technical guideline for
R&D and evaluation of biosimilars, issued by the Center of
drug evaluation (CDE) China on 28th February 2015, the draft
guideline on biosimilar medicinal product TMMDA, the official
Mexican standard NOM-257-SSA1-2014 for biotechnological
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FIGURE 1 | Structure of data presentation in result section. *Under each agency the psychochemical requirements covered are mAb structure, immunological
properties, biological activity purity impurity and contaminants cell lines quantity,specifications. **Under each agency, the in vivo (non-clinical) studies requirements
covered are pharmacokinetics, pharmacodynamics, immunogenicity, safety pharmacology, toxicology, carcinogenicity, local tolerance. ***Under each agency the
clinical requirements covered are pharmacokinetics, clinical efficacy, clinical safety, extrapolation to other indications, pharmacovigilance, risk management plan.
medications, were translated into English by a professional
agency and/or a translated version was obtained from local
resources for further review.
Apart from the national guidelines, the quality considerations
highlighted in this article are based on ICH Q5A to Q5E-
quality of biotechnological products guidelines, ICH Q6B
for specifications and ICH Q11 for the development and
manufacture of drug substances (chemical entities and
biotechnological/biological entities). The reviewed ICH
guidelines were those published during November 1995 to
November 2004 whereas national guidelines were issued from
2002 until February 2018. Refer to Supplementary Table 2
presenting country, agency and guidelines referred for detailed
review.
Themain aim of the research was to evaluate and identify gaps
in regulations and marketing authorization practices followed
in emerging markets, hence well-established agencies i.e. EMA,
WHO, USFDA and BGTD were selected as reference agencies.
The criteria to select reference agencies are as follows: EMA is
considered as a pioneer in biosimilar regulation development
and the first agency to come up with detailed regulations
for biosimilars. Apart from that, many emerging agencies are
following EMA’s published biosimilar guidelines as reference
documents in the absence of detailed guidelines published by
their own agency. When it comes to emerging agencies, the
WHO regulatory framework is taken as the benchmark for
developing national regulations. Hence WHO is considered a
reference agency. The USFDA is considered as an advanced
regulatory agency and believed to be more transparent and
vigorous in terms of regulatory expectations. BGTD Canada
is an ICH member country and co-chair to International
Pharmaceutical Regulators Forum (IPRF). It also works in close
association with emerging agencies i.e. Brazil, Russia andMexico.
At the moment, PMDA Japan is excluded from the research
since most of the emerging agencies follow EMA, WHO, USFDA
or BGTD for biosimilars. The TGA Australia is excluded since
the regulations are fully aligned with those of the EMA and no
differences in quality, nonclinical and clinical requirements can
be observed.
The emerging agencies i.e. Brazil, Russia, India, China, South
Africa, Turkey, and Mexico are selected due to their growing
emerging economies, increased patient populations, demand for
biosimilars and evolving regulatory agencies.
The data pertaining to biosimilarity principles, comparability
exercise, selection of reference product, physico-chemical
characterization, manufacturing process and specification
determinations, in vitro and in vivo studies, pharmacokinetic
(PK) and pharmacodynamic (PD) studies, immunogenicity
assessment, PK and PD studies in humans, comparative clinical
trials, clinical safety studies, extrapolation to other indications,
pharmacovigilance and interchangeability were extracted
from the aforementioned guidelines. Subsequently, the data were
qualitatively compared, and visible similarities and/or differences
were identified for emerging markets.
RESULTS
The summary of this review research is presented as biosimilarity
principles, reference product selection and comparability
exercise. The comparability criteria are further specified into
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quality/characterization (physicochemical characterization,
manufacturing process, overages and compatibility), non-
clinical studies (in vitro and in vivo studies), clinical studies
(PK and PD studies, clinical efficacy and clinical safety studies,
extrapolation to other indications, pharmacovigilance and risk
management plan). Each criterion is further divided, based on
agency in sequential order as EMA, WHO, USFDA, BGTD/HC
and BRICS-TM agencies. For ease of understanding, refer to
Figure 1 pertaining to structure of data presentation in the
results section.
Biosimilarity Principles
The biosimilars are therapeutically similar to an originator
biological product and proving these attributes involves
comparative analytical, non-clinical and clinical testing with the
reference product selected (Olech, 2016). The objective of the
development plan of such products is to prove similarity in terms
of quality and efficacy to the reference biological product. With
regards to safety, better safety profile is allowed; they can also
expect to have lower impurity profile than the originator.
The biosimilarity principles encompass terminology,
development approach, basis of biosimilarity, demonstration
of biosimilarity with the chosen reference product, simplified
approach and regulatory framework across advanced regulatory
agencies and national regulatory authorities of BRICS-TM.
Different terminologies such as similar biological medicinal
product, biosimilar, similar biological product, biosimilar
biological drug are being used to define similar versions of
reference biological/ biotechnological products. The stepwise
development approach for characterization, in vitro and in vivo
non-clinical studies and clinical studies is uniform across well-
established regulatory agencies and a totality-of-the-evidence
approach for assessment of biosimilarity is followed. However,
approach to biosimilarity is not clear in some of the agencies of
emerging markets.
In general, according to a step-wise approach, the
biosimilarity of a proposed biological product should be
demonstrated by the totality of the evidence, whereas minor
quality differences may be justified by pre-clinical or clinical
studies. Additionally, WHO indicates the need for safety data
for differences that are not explained. In addition, companies
may use various tools such as technical advice or consultation
to receive advice on scientific matters by discussing biosimilar
development with advanced regulatory agencies such as USFDA
and EMA by arranging formal meeting (CBER, 2018). When
it comes to biosimilarity demonstration, Brazil, Russia and
Mexico stresses more comparative clinical studies or no defined
recommendations in published guidelines.
Depending upon the demonstration of biosimilarity, the
application can be filed as stand-alone or an abbreviated
filing with ANVISA, Brazil. Simplified approaches (in terms
of smaller clinical trial/s if bioassay is known to be clinically
relevant or the number of patients may vary depending upon
the endpoints) is defined by the EMA, WHO and USFDA
with prior regulatory opinion; however, such transparency
is yet to be defined in detail by other BRICS-TM agencies
except TMMDA and SAHPRA (Anvisa, 2010; CFDA, 2014;
Cofepris, 2014; MCC, 2014; Russian-federation, 2014; CBER,
2015; EMA, 2015; CDSCO, 2016; General-Directorate-for-
Pharmaceuticals-and-Pharmacy, 2017; WHO, 2017; WHO-TRS,
2017).
Reference Product Selection
The reference biological product selected for comparability
studies must be licensed with full dossier including quality,
safety and efficacy. For most agencies, it must be sourced
from the same territory where biosimilar authorization is
requested. Supplementary Tables 3, 4 refer to reference product
characteristics according to advanced agencies i.e. EMA, USFDA,
BGTD/HC and BRICS-TM agencies, respectively. The WHO
leaves the decision to the NRA to define criteria for the reference
product selection; this is evidence based on factors for selection
of the reference biologic determined by CDSCO, India (Rushvi
et al., 2016).
The (EMA, 2014b) guidelines state acceptance of non-EEA
authorized comparator for certain clinical studies and in vivo
studies during development of Quality targeted product profile
(QTPP) of the proposed biosimilar product, subject to such
comparator being authorized by regulatory authorities having
similar scientific and regulatory standards to the EMA. The
bridging data is expected in terms of quality, non-clinical
or clinical side-by-side comparability between the reference
product, non-EEA authorized comparator product and proposed
biosimilar product. In the EU, the data generated from another
country’s reference product can be used as supporting data for
biosimilarity assessment. The EMA andUSFDA expect that when
there is usage of a third country reference product, in addition
to bridging data generation, the pathway is to be discussed in
advance, whereas, a similar approach is yet to be defined with
emergingmarket regulatory agencies (Anvisa, 2010; CFDA, 2014;
Cofepris, 2014; MCC, 2014; Russian-federation, 2014; CDSCO,
2016).
The reference product must be identified in terms of brand
name, pharmaceutical form, strength, number of batches, lot
number and age of batches. It is expected that the originator
product will be used and multiple batches with different shelf
lives remaining throughout the development and comparability
studies will be tested. As for WHO, if the reference biological
product is manufactured at different locations but authorized
under a single license for global distribution, then it will be
considered as the same reference product. In such scenarios,
the reference product manufactured in different sites can be
used as RBP for biosimilar development (Health-Canada/BGTD,
2012, 2016; WHO-TRS, 2013; CBER, 2015; EMA, 2015; General-
Directorate-for-Pharmaceuticals-and-Pharmacy, 2017).
Biosimilar products are not allowed to be used as reference
products across all agencies, except COFEPRIS (Mexico). It is
observed that only COFEPRIS accepts a biosimilar product as
a reference product in case of non-availability of a reference
product (Cofepris, 2014).
Comparability Exercise
The comparability exercise is a crucial element to prove similarity
of a proposed similar biological product. It involves side by
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side comparison of sequential comparative studies against a
reference product starting from characterization (e.g., physico-
chemical characterization, manufacturing process, compatibility,
overages) of the active substance to the final product, followed
by non-clinical and clinical studies. In general, each agency
expects that significant differences observed in previous steps are
to be explained in subsequent studies. The justified variations
in excipients, cell lines, manufacturing processes, container
closures, test parameters, impurities, storage conditions, shelf
life and lower immunogenicity may fall within the scope of
biosimilarity.
Differences in safety parameters, such as reduced toxicity or
number and type of adverse reactions, may not prevent the
establishment of biosimilarity. However, efficacy differences, e.g.,
altered glycosylation profile would most likely be considered
outside the bounds of biosimilarity principles.
A further aspect related to extrapolation of indications
is the shift from acceptance to conditional acceptance
(Supplementary Table 5). It is clearly visible that
interchangeability decision falls within the scope of each
member states of the EU (Minghetti et al., 2012), whereas for
Canada, the decision of is out of scope of regulators but in hands
of province/territory. The USFDA allows interchangeability
subject to additional studies, whereas this often remains
unspecified in the less mature regulatory agencies. Pediatric
research or extrapolation of efficacy in the pediatric population
is indicated under PREA by US authority whereas the same is at
a very basic stage in emerging markets (Supplementary Table 5;
EMA, 2007; Anvisa, 2010; WHO-TRS, 2013; CFDA, 2014;
Cofepris, 2014; EMA, 2015; MCC, 2014; Russian-federation,





A typical antibody is made up of four polypeptide chains
wherein each chain consists of one heavy chain and one light
chain, connected via disulfide bridges or bonds and has amino
terminal variable region/s. The number of amino acids at amino
terminal varies for different antibodies. The complementarity
determining region (CDR) is the most variable part of the
variable region and it comes together at an amino terminal
to form an antigen binding site. The class and sub-classes of
monoclonal antibodies are defined based on isotypic, allotypic
and idiotypic determinants.
The Y-shaped antibody is made up of one constant region (Fc)
and two variable regions (Fab) with antigen binding sites. The
Fc region exhibits limited variability and is made up of two light
chains and five heavy chains, with linkage of carbohydrate group
at the heavy chain (Wiley-publication, 1998).
The primary step of the comparability exercise starts with
characterization of a reference biological product to establish
the Quality targeted product profile (QTPP) of the proposed
biosimilar. While performing characterization of a reference
product containing an ingredient i.e. albumin, the extraction
of albumin is expected by appropriate extraction methods
so that the structure of the mAb is not modified. The
physicochemical requirement for a mAb is indicated in Figure 2.
The information provided herewith is based on EMA and
WHO guidelines specific to monoclonal antibodies. BRICS-TM
agencies, except SAHPRA, have not published a specific mAb
guideline.
EMA
mAb structure: As part of physico-chemical characterization of
mAbs, the EMA has recommended performing primary and
higher order structure identification covering class and sub-
classing determinations, the type of chain (kappa and/or lambda)
involved and detailed characterization of primary structure.
Guidelines further specify requirements pertaining to amino
acid sequencing as well as conformation of amino and carboxy
terminal at Fab- and Fc- region respectively. The intra and inter
disulfide bridges to be determined along with their integrity and
mismatches with respect to the reference medicinal products.
The free sulfhydryl groups are to be identified as well. The
carbohydrate content, its structure and oligosaccharide pattern
are to be identified and confirmed. The glycosylation site on
the Fc- region is required to be analyzed with its occupancy.
The presence or absence of glycosylation site is to be confirmed
and characterization to be done if confirmed positive. Apart
from the above, the glycan structure is to be characterized with
mannosylation, galactosylation, fucosylation, and sialylation with
distribution of main glycan structure.
Guidelines on similar biological medicinal products (EMA,
2014b, 2015, 2016) define requirements pertaining to all
biotechnological/biological products including monoclonal
antibodies. The physico-chemical characterization section of
this guideline states requirement for description for structural
FIGURE 2 | Monoclonal antibodies-Physiochemical characterization
parameters.
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elements such as active sites, receptors, ligand binding sites and
features for signal transduction. Additional characterization
with respect to in vivo disposition of active substance while
administering product and interactions between active substance
and excipients would be necessary.
Immunological properties: The antigen binding fragment (Fab)
region of a mAb is critical for its immunological properties. EMA
recommends analyzing antigen binding assay at defined regions
including affinity, avidity and immunoreactivity, as feasible to be
performed. In addition to binding assay, cytotoxicity evaluation
at unintended target issue and cross-reactivity need to be
determined. The epitope (the part of antigen which attaches to
an antibody) needs to be characterized, biochemically identified
and determined including the base molecules. The identification
of complementarity determining regions is essential or needs to
be justified. It is further stated that evaluation of binding and
activation and/or effector functions should be evaluated even
though the proposed biological activity does not demand such
function. The above immunological studies are expected to be
performed against the reference biological product and must be
comparative in nature.
Biological activity: The biological activity is generally defined
as the ability of a product to give biological results/effects.
EMA expects appropriate in vitro assay(s) for assessment of
biological activity. The in vivo assays if performed need detailed
justification. The mechanism of action including its importance
and consequences of product effector functions with respect
to safety and efficacy of product calls for discussions. Such
discussions should be based on a detailed analysis of antibody-
dependent cell-mediated cytotoxicity (ADCC), cytotoxic
properties (e.g., apoptosis), complement binding and activation
ability, other effector functions i.e., Fc- gamma receptor binding
activity and neonatal Fc- receptor (FcRn) binding activity. The
above biological studies are expected to be performed against
the reference biological product and must be comparative in
nature.
Purity, Impurity and Contaminants: mAbs can express
heterogeneity due to multiple factors such as C-terminal lysine
processing, N- terminal pyroglutamate, deamidation, oxidation,
isomerization, fragmentation, disulfide bondmismatch, N-linked
oligosaccharide, glycation. This results in different molecular
entities for mAbs. To identify purity or impurity profiles of
mAbs, the orthogonal methods which include physico-chemical
property determinations need to be performed.
The formation of aggregates, sub visible and visible
particulates needs investigation and close monitoring during
batch release and stability studies. Multimers and aggregates
need to be characterized appropriately.
Process related impurities such as host cell DNA, cell
culture residues, downstream processing residues demand
identifications as well as qualitative and/or quantitative
evaluation.
Contaminants (outside the scope of the manufacturing
process) are expected to be controlled or restricted. Appropriate
additional testing is required to be done, if pro-inflammatory
contaminants are suspected.
Cell lines: Sufficient monoclonal cell line information is
expected, but detailed specific procedures prior to the isolation
of the monoclonal cell line i.e. cell fusion, viral transformation,
gene library of phage display screening, application of in silico,
in vitro or in vivo technologies are not required to be described
in great detail. Origin and characteristics of parental cells
need to be documented and immortalization approach to be
defined.
Quantity: The quantity of finished product should be
determined based on appropriate physicochemical and/or
immunochemical assays. The same can be determined based on
biological assays subject to demonstration of correlation between
quantity and biological activity.
Specifications: Specification is determined based on batch
data, manufacturing experience, characteristics of the product,
other controls used in the process etc. The ICH Q6B should
be followed for drug substance and drug product for test
selection. In general, more than one specific identity test,
purity, impurities, potency and biological activity test to
be included. The glycosylation test should be performed
for the products where posttranslational modification could
occur. Other general tests as applicable to formulations need
to be covered e.g., solubility, extractable volume, bacterial
endotoxin.
The acceptance criteria need to be defined based on lots
used in studies i.e. manufacturing consistency, non-clinical and
clinical studies, stability studies and other relevant development
data. The analytical method validation is to be submitted as part
of the marketing authorization application dossier. Compendial
reference methods are expected to be used from European
pharmacopeia (Ph Eur) and fromWHO.
During pre-formulation studies, the stability of active
substances needs to be proved by establishing degradation
pathways whereas for formulation, experimental data with
different quantities of suitable excipients is expected. If the
product is lyophilized, then the usage of lyoprotectant must be
determined for process optimization through in-process stability
study. Real time, real condition stability studies are required as
part of routine stability studies in line with ICHQ5C (EMA, 2000,
2016).
WHO
mAb structure: Supplementary Table 6 presents differences
between EMA and WHO for mAb physicochemical
characterization requirements. Although WHO has defined
primary and higher order structure characterization, specific
mandates pertaining to class and sub-class determination and
kappa and/or lambda chain confirmation remain unspecified,
as it is the case with the EMA. The carbohydrate structure,
glycosylation pattern and glycan evaluation requirement are the
same as those of the EMA.
WHO does not refer to structural elements, in vivo
disposition, interactions, amino acid sequencing with variability
at N- and C- terminal, disulfide bridges and free sulfhydryl group
requirements. The rest of the parameters of characterization are
aligned with those of the EMA.
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Immunological properties: The expectations pertaining to
binding assays are spelled out in guideline without further detail.
Biological activity: It is expected that appropriate assays will
be performed; however, there is no clarity with respect to in vitro
or in vivo. Further it is stated that ADCC binding ability to Fc-
gamma receptor binding activity, neonatal Fc receptor (FcRn),
complement (C1q) binding, Fc and Fab related functions are to be
performed. It is unclear whether such test is required; in the case
the ADCC-related mechanism of action does not impact safety
and efficacy.
Purity, Impurity and Contaminants: Investigations,
identifications and quantifications of structural heterogeneity are
expected.
Impurity profiling as well as process related impurities are
required to be considered, however use of orthogonal methods
is not defined, either for purity or impurity tests. The status of
non-clarity prevails for multimers, aggregates, particulates, and
contaminants.
Cell lines: The SBP manufacturer/applicant can use different
monoclonal cell lines than the reference biological product
(RBP) to produce a biosimilar mAb, when the structure of the
molecule and its clinical profile remain unchanged; but in-depth
requirement is not specified. However, it is recommended to use
the same monoclonal cell line as RBP.
Quantity: The quantity of biosimilar product in final
presentation is determined based on biological activity and
expression system.
Specifications: It is expected that specifications will be
determined based on the manufacturer’s experience with similar
biologic product (SBP) and experimental results with SBP and
RBP. The tests are to be performed as per pharmacopeia
monograph plus additional test as appropriate. The acceptance
criteria are to be decided based on a sufficient number of lots and
should not be wider than the variability range of the RBP during
entire shelf life.
The analytical methods for characterization should be
scientifically sound and qualified but it is not necessary that they
be validated, whereas for lot release validation is expected. The
reference materials and standards are expected to be sourced
from the WHO.
Real time and stability under real conditions for the SBP
is expected, whereas experimental stability data and in process
stability data are not defined. It is expected to have comparative
head-to-head accelerated stability studies between SBP and RBP
and non-comparable stress studies. Apart from this drug product
and drug substance, stability studies are expected in intended and
in the representative container closure system (WHO-TRS, 2013,
2017; WHO, 2017).
USFDA
mAb structure: The physico-chemical characterization
requirements are specified in guidance documents pertaining
to biotechnological/biological products. The PEGylation
characterization is unique to USFDA requirement. Appropriate
physico-chemical methods i.e. sodium dodecyl sulfate
polyacrylamide (SDS-PAGE), Isoelectric focusing (IEF), High-
performance liquid chromatography (HPLC), mass spectrometry
(MS) are required to be used. Binding assays to be performed and
epitope should be defined biochemically; the quantification of
antibody binding activity needs to be performed by combination
of tests such as affinity, avidity and immunoreactivity.
Immunological properties: The requirement is in line with
WHO immunological properties.
Biological activity: in vitro and in vivo assays are required
without further recommendation on product effector
functions.
Purity, Impurity and Contaminants: The risk of impurities
and contaminants are additional for biological products due
to usage of living systems for manufacturing (Christl et al.,
2017). It is expected that structural heterogeneity and aggregates
will be characterized. The purity and impurity tests are to
be performed using orthogonal methods whereas there is
need to characterize for known and potential impurities. The
contaminants expectation remains in line with those of the EMA.
Cell lines: It is recommended to minimize differences between
reference product’s expression construct and the one proposed
for the biosimilar product: justification for differences is to be
provided.
Quantity: Potency must be defined based on assay(s).
Specification: Accelerated and stress stability studies under
multiple stress conditions such as high temperature, freeze thaw,
light exposure and agitation are required for appropriate physico-
chemical and functional comparison of the stability profile of
the proposed product against that of the reference product.
Sufficient real time and real condition data of the proposed
product is to be provided in support of the shelf life (CBER,
2015a,b).
BGTD/Health Canada (HC)
mAb structure: BGTD/HC has not published a guidance
document exclusive to mAbs. However, it has advised
to reference ICH Q5E pertaining to comparability of
biotechnological/biological products subject to changes in
their manufacturing process. In line with ICH Q5E, higher order
(secondary, tertiary and quaternary) structures for mAb are
to be determined for proving a suitable comparability exercise
for the proposed biosimilar. About amino acid sequencing,
disulfide bridges, characterization for Fab- and Fc- region and
carbohydrate content requirements remain unspecified.
Immunological properties: The antigen binding assay and
epitope requirements are aligned with the EMA guideline.
However, cytotoxicity evaluation, cross-reactivity and
complementary ability evaluation remains undefined.
Biological activity: Relevant functional assays are indicated
to be performed but details i.e. cytotoxicity (ADCC), cytotoxic
properties (e.g., apoptosis), complement binding and activation
ability, other effector functions i.e., Fc- gamma receptor binding
activity and neonatal Fc- receptor (FcRn) binding activity remain
undeclared.
Purity, Impurity and Contaminants: The fact sheets of
BGTD/Canada demand purity testing for both the drug
substance and the drug product. It also specifies identification,
characterization and biological activity evaluation of impurities,
if non-relevant with reference product. BGTD expects to have
highly similar or same level (% of impurities) to comply with
biosimilarity principle.
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The general requirement for molecular heterogeneity is stated;
however qualitative or quantitative nature of methods is not
specified.
The requirements pertaining to multimers, aggregates
and particulates are in line with those of the WHO,
whereas contaminants are as per EMA requirements
(Health-Canada/BGTD, 2017).
Cell lines/ Quantity: The expectation of cell lines as well
as depth of information required in marketing application for
biosimilar is yet to be spelled out. The views of BGTD/Canada for
quantity determination of finished product need to be specified in
the guideline.
Specifications: It is indicated that appropriate specification is
to be chosen for the biosimilar, but further information such as
determination of specifications, acceptance criteria, method of
analysis and its validation and criteria for stability studies are not
provided in detail (Health-Canada/BGTD, 2016).
BRICS-TM
Supplementary Table 7 reveals the comparative quality
attributes for biosimilar development across BRICS-TM
markets.
ANVISA: Resolution RDC n◦ 55/2010 specifies requirements
pertaining to primary, secondary, tertiary and quaternary
structure characterization; however immunological properties
are not defined. The biological activity is expected to be
determined, however requirement for type of assays are
not defined. Impurity profile, process related impurities and
contaminants are expected to be characterized. The other
requirements for purity and heterogeneity are unclear. The
criteria pertaining to cell lines, quantity and specifications are not
defined (Anvisa, 2010).
Russian Federation: Russian Federation Law number 61-
FZ on the circulation of medicines in Russia announces little
about biosimilars. Hence characterization specifics for mAbs or
any other biotechnological/ biological products are difficult to
understand for manufacturers (Russian-federation, 2014).
CDSCO: The CDSCO India has established guidelines on
similar biologics based on WHO guidelines. The requirements
for mAb characterization remain in line with those of the WHO,
whereas immunological property criteria remain unspecified.
The biological assays are expected to be determined; however,
the types of assays are not defined. Evaluation of multimers,
aggregates and process related impurities are expected to be
carried out. As to orthogonal methods for purity, contaminants,
heterogeneity, these remain unspecified. The cell lines and
quantity essentials are not spelled out. The qualified assays are
required for characterization, however detailed requirements are
unavailable (CDSCO, 2016).
CFDA: It is recommended to identify and characterize
primary and advanced structure (secondary/tertiary/quaternary),
structural heterogeneity and glycosylation. The expectations for
immunological properties are to have comparative qualitative
and quantitative analysis for Fab- and Fc- fragment including
affinity for antigens, CDC and ADCC activity, affinity for
FcRn, Fc gamma and C1q receptors. Purity to be determined
in terms of hydrophobicity, charge and molecular size variant
and various type of post translation modifications including
glycosylation. Process impurities must be considered and new
impurities to be characterized. For the biological activity it is
expected that bioactivity test will be performed, consistent with
the reference drug, however, details are not provided. The cell
lines and quantity criteria remain undefined. The specifications
should be consistent with the reference drug. It is expected that
sensitive and advanced analytical techniques and methods will be
used to detect potential differences between candidate drug and
reference drug. It is recommended to use sensitive conditions
for accelerated and forced degradation stability studies (CFDA,
2014).
SAHPRA (previously known as MCC): The biosimilar and
reference product should be structurally, physico-chemically
and biologically similar as per MCC guideline. The Medicines
Control Council (MCC) issued biosimilar characterization
requirement which remains unchanged with WHO/EMA. The
immunological properties, cell lines and quantity criteria are
undefined, whereas biological activities are expected to be
characterized by both in vitro and in vivo assay(s). Heterogeneity
and contaminants are not specified but are expected to have test
performed for aggregate formation test and for quantifications
of impurities. The process related antibody impurities should be
considered. Validated analytical techniques are expected to be
used for characterization (MCC, 2014).
TMMDA: Turkish draft biosimilar guideline is in parallel with
EMA’s overarching biosimilar guidelines. It is stated that this
guideline could apply for any biological medicines. However,
TMMDA has not published a specific guideline on mAbs yet.
According to the guideline, a physico-chemical
characterization programme should include primary and higher
order structures of the biosimilar. Any detected differences
between the biosimilar and the reference medicinal product
should be justified with respect to the micro-heterogeneous
pattern of the reference product. The immunological functions
of mAbs and related substances (e.g., fusion proteins based on
IgG Fc) should be fully compared. This would normally include
a comparison of affinity of the products to the intended target.
In addition, binding affinity of the Fc to relevant receptors
(FcγR, C1q, and FcRn) should be compared unless justified.
Appropriate methodology should also be employed to compare
the ability to induce Fab- and Fc-associated effector functions.
Biological assays using different and complementary
approaches to measure the biological activity should be
considered, as appropriate. Depending on the biological
properties of the product, different assay formats can be used
(e.g., ligand or receptor binding assays, enzymatic assays,
cell-based assays, functional assays), taking into account
their limitations. Complementary or orthogonal approaches
should be followed to accommodate limitations regarding
validation characteristics of single bioassays. State-of-the-
art analytical technologies following existing guidelines and
pharmacopoeial requirements should be applied to identify
both of product-related and process-related substance and
impurities and the potential risks related to these identified
impurities (e.g. immunogenicity) will have to be appropriately
documented and justified. The cell lines criteria remain
unspecified. The rationale used to establish the proposed range
of acceptance criteria for routine testing should be described.
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The claimed shelf life of the product should be justified with full
stability data obtained with the biosimilar medicinal product.
Comparative real-time, real-condition stability studies between
the biosimilar and reference medicinal product are not required
(General-Directorate-for-Pharmaceuticals-and-Pharmacy, 2017).
COFEPRIS: Though Mexico has used WHO Similar Biologic
Products (SBP) guidelines as reference to establish Official
Mexican Standard NOM-257-SSA1-2014, the guideline
pertaining to mAbs biosimilar is not referenced. Hence
no specific criteria for characterization are defined. The
immunological properties, biological activity, purity, impurity,
contaminants, cell lines, quantity and specifications are unclear,
since no reference has been given to mAb specific EMA guideline
(Cofepris, 2014).
Manufacturing process
Comparative characterization of manufacturing process would
be challenging since reference product manufacturing process
detail would be confidential. However, the agency’s expectation
for the manufacturing process is to produce targeted product
having comparable molecular and quality profile. Apart from
that, the process must be capable of manufacturing product of
consistent quality. Appropriate in-process control parameters
need to be defined at the time of process development. The
platform manufacturing approach can be utilized with proper
justification and evidence.
The process needs to be fully validated including validation of
viral reduction study as per ICH Q5A; also, if material of animal
origin is used then TSE guidelines are to be considered.
WHO recommends to optimize the process so as to minimize
differences between SBP and RBP for reduced clinical testing and
lesser impact on safety and efficacy (WHO-TRS, 2017).
BGTD expects that the applicant submits the proposed
comparison in the manufacturing process to the reference
biologic drug, in case such information is available (Health-
Canada/BGTD, 2016).
Overages
Appropriate overages to be included based on variability of
bioassay in in vivo condition.
Compatibility
It is required to perform compatibility between biological
substance and excipients. The investigation of interaction study
is mandatory if primary packing materials is different than
reference product.
Non-clinical Studies
WHO, EMA and FDA have described non-clinical evaluation in a
stepwise manner and to be comparative. The primary objective of
such studies is to explain differences observed in characterization
studies.
As per EMA, WHO, BGTD/HC, CDSCO and TMMDA,
in vivo non-clinical studies may be necessary, if characterization
and in vitro studies warrant such studies (EMA, 2014a; CDSCO,
2016; Health-Canada/BGTD, 2016; General-Directorate-for-
Pharmaceuticals-and-Pharmacy, 2017; WHO-TRS, 2017).
According to USFDA limited animal toxicity data might be
sufficient when comparative structural and functional data to
prove analytical similarity (CBER, 2015).
ANVISA insists that comparative in-vivo non-clinical studies,
covering pharmacodynamic studies and repeat-dose toxicity
studies with toxicokinetic should be submitted, conducted in
relevant species (Anvisa, 2010).
The determination of in vivo studies remains non-clarified
with MCC/SAHPRA guideline, while COFEPRIS remains silent
on non-clinical requirement (Cofepris, 2014).
In vitro studies
EMA
Non-clinicfal studies should be performed in a step-wise manner,
starting with comparative in vitro studies for binding and
functional assays following with second step of additional
in vivo studies, if necessary. The non-clinical studies should
be performed on sufficient batches representing the proposed
clinical trial batch. In vitro assays should be inclusive of binding
target antigen(s) assay, binding assays with Fc gamma (FcγRI,
FcγRII, FcγRIII) receptors, FcRn and complement (C1q), Fab-
associated functions e.g. soluble ligand neutralization, activation
or blockade of receptor, Fc-associated functions e.g., ADCC,
CDC, complement activation, depending on the type of mAb.
It is expected to have comparative studies with capability
to identify differences between the similar biological medicinal
product and the reference medicinal product. In general, tissue
cross-reactivity studies are not recommended. ADCC and CDC
evaluation does not have to be performed for mAbs directed
against non-membrane bound targets.
To decide in vitro studies should reference product
information about receptors or antigens involved in pharmaco-
toxicological and pharmaco-kinetics properties to be studied.
Accordingly, comparative binding assays signal transduction and
function activity/viability should be performed, and differences
should be justified.
Based on the batch-to-batch variability and assay, the number
of lots for reference product to be decided and justified. In-vitro
studies should cover all attributes of mAbs, even though each of
these not to be considered as essential for the therapeutic mode
of action (EMA, 2012, 2014a).
WHO
In addition to EMA requirements, WHO has specified binding
studies for antigen, Fc receptors and Fab- (i.e., neutralization of
soluble ligand, receptor activation/blockade, reverse signaling via
activation of membrane-bound antigen) and Fc- (i.e., ADCC,
ADCP, CDC) associated functions (WHO-TRS, 2017).
USFDA
The pharmacologic activity of protein products should be
evaluated by in vitro functional assays such as biological assays,
binding assays, and enzyme kinetics. These assays should be
comparative thus they can provide evidence of similarity or
reveal differences in the performance of the biosimilar. The
requirements are similar those of the EMA and those of theWHO
(CBER, 1997).
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Health Canada/BGTD
Non-clinical in vitro studies are recommended, however no
further details i.e. of binding target antigen(s) assay, binding
assays with Fc gamma receptors, FcRn and complement
(C1q), Fab- and Fc-associated functions, are available (Health-
Canada/BGTD, 2016).
BRICS-TM
The in vitro assay related information is not defined in the
guideline published by ANVISA, the Russian federation, CFDA
and COFEPRIS (Anvisa, 2010; CFDA, 2014; Cofepris, 2014;
Russian-federation, 2014). The CDSCO defines in vitro cell
based bioassays i.e. cell proliferation/ cytotoxicity/ neutralizing/
receptor binding assays to be performed as part of in vitro
studies (CDSCO, 2016). The requirements for SAHPRA and





For biological products, in vivo studies are to be performed
if in vitro studies show significant differences (i.e.
new/modified structure, quantitative difference in quality
attributes, formulation difference etc.) between the proposed
biological product and the reference product. Differences in
structure/quantity/formulation (novel excipient) /inherent
nature of molecule, presence of relevant quality attributes
different from the reference product might become a key
deciding parameter for in vivo studies. For additional
information transgenic animal/transplant models can be
considered. Direct human studies can be done if a relevant
animal model is unavailable. The duration of the study should be
justified based on PK behavior of the mAb and its clinical use.
PKPD: The dose concentration-response assessment studies
need to be performed considering targeted human dose
and quantitatively compared with reference product. The
study needs to be performed as per Article 4 of Directive
2010/63/EU.
Repeated-dose toxicity: It is expected that a flexible approach
is considered only if non-human primate is the relevant species.
Comparative studies with inclusion of one single dose of
reference product and biosimilar and/or one gender and/or
no recovery animals/evaluation of in-life safety parameters
need to be performed. The highest dose of the range can be
selected for one-dose evaluation and justification should be given
accordingly. EMA does not recommend repeat dose toxicity
study in non-relevant species to assess non-specific toxicity to
justify differences in production processes.
Immunogenicity: Though animal immunogenicity is not
predictive in human, blood samples should be taken for future
pharmaco/toxico kinetic evaluation.
Safety Pharmacology, Reproduction Toxicology and
Carcinogenicity: Not required.
Local tolerance: Required only if novel excipients for proposed
ROA are used and such study can be part of other in vivo studies
(EMA, 2007, 2014a).
WHO
PK and/or PD: Comparative study including intended exposure
in humans must be performed via dose-response assessment, if a
relevant animal model is available.
Repeat-dose toxicity study: It is not recommended in non-
human primates. The highest known dose needs to be selected
if quantitative differences are required for evaluation. For
qualitative differences, the relevant doses should be selected
so that potential differences between RBP and SBP can
be identified. Antibody measurements should be included
to support toxico-kinetic data interpretation and the overall
comparability exercise.
Immunogenicity study: WHO has advised to withdraw blood
samples in case this study is required for interpreting PK/TK.
Local tolerance studies: to be evaluated depending upon route
of administration and can be carried out as part of repeat-dose
toxicity study.
Safety pharmacology, reproductive toxicology, genotoxicity
and carcinogenicity studies are generally not required unless
justified based on RBP properties (WHO-TRS, 2013).
USFDA
In vivo studies are advised to be performed in line with preclinical
safety evaluation of biotechnology-derived pharmaceuticals S6
(R1) (CBER, 1997; EMA, 2007). The pharmacologic activity
of protein products should be evaluated by in vitro functional
assays as well. Animal toxicity studies are considered useful if
there are uncertainties about the safety of a biosimilar product
after extensive structural and functional characterization. The
scope and extent of animal toxicity data is dependent upon
information on the reference product, biosimilar product and
known similarities and differences between the two.
It is strongly recommended to discuss with the Agency for not
conducting animal studies or scope and extent of these studies
(CBER, 2018). Even though animal PK and PD studies were
conducted, the need for human PK and PD studies remains.
Animal immunogenicity assessment helps to interpret animal
study results but generally do not predict potential immune
response in human.
Health Canada (HC)/BGTD
The guideline indicates that in vivo studies are not required,
if similarity is proven in the previous steps. Details about in
vivo criteria, if required, are unavailable (Health-Canada/BGTD,
2016).
BRICS-TM
Figure 3 indicates comparative nonclinical (in vitro and in vivo)
requirements across BRICS-TMmarkets.
PD studies for intended therapeutic indication and repeat-
dose toxicity studies including toxicokinetic in relevant species
are mandatory for ANVISA; however detailed requirements
are not specified (Anvisa, 2010). Such study information
is unavailable from the Russian federation and COFEPRIS
(Cofepris, 2014; Russian-federation, 2014).
Frontiers in Pharmacology | www.frontiersin.org 10 September 2018 | Volume 9 | Article 1079
Rahalkar et al. Biosimilars Regulatory in BRICS-TM Markets
FIGURE 3 | Comparative non-clinical attributes across BRICS-TM markets. n/d, not defined; HED, human equivalent dose; PKTK, pharmacokinetics toxicokinetics.
The SAHPRA guideline states that in vivo animal studies,
with at least one repeat-dose toxicity study with toxico-
kinetic measurements is required to be presented to show
comparative toxicity and bioactivity. Such study should analyze
immunogenicity as well as relevant specific safety concerns.
Other toxicological studies are not required unless needed, based
on reference product (MCC, 2014).
In vivo studies may not be required if similarity is proven
in the previous steps as stated in CDSCO guideline. A repeat-
dose toxicity study is recommended to be performed, at
minimum one repeat-dose study, with at least 1X of human
equivalent dose (HED), in a relevant animal model, with
intended ROA, for not <28 days with 14 days recovery period.
For a pharmacologically relevant animal model, the intended
route of administration should be included. In case a relevant
model is not available, studies should be performed in two
species i.e., one rodent and other non-rodent and Schedule Y
should be followed for route of administration. Moving further
to immunogenicity, the CDSCO requires comparative antibody
responses in a suitable animal model study. It should be part
of sub-chronic repeated-dose study. The local tolerance studies
and other toxicological studies requirements are aligned with
WHO, whereas safety pharmacology, reproductive toxicology,
mutagenicity and carcinogenicity studies are generally not
required unless justified based on the RBP’s properties (CDSCO,
2016).
The CFDA needs comparative non-clinical in vivo studies as
far as possible. Single dose and repeat-dose toxicity studies are
essential to be performed (CFDA, 2014).
The TMMDA requirements are defined as in line with
EMA’s overarching biosimilar guidelines (General-Directorate-
for-Pharmaceuticals-and-Pharmacy, 2017).
Clinical Studies
Pharmacokinetics and Pharmacodynamics studies
EMA
Pharmacokinetics (PK): The clinical data need to be obtained
using the proposed biosimilar product, from a commercial batch,
to ensure similarity of quality profile between comparability and
commercialized batch.
Comparative PK is expected, and comparability needs to
be proved considering clearance and/or half-life of therapeutic
protein. Methods used for analyzing immunoassays and
bioassays should be validated. The bio-analytical method should
be capable of identifying and analysing the parent molecule
and/or degradants, if any.
PK studies should be performed in healthy volunteers,
screened for homogeneity to perform single-dose study.
The preference is single-dose, cross-over with PK profile
characterization including late elimination phase. Parallel group
design can be explored for longer half-life and/or higher
immunogenicity risk. When PK studies are performed in healthy
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volunteers, data needs to be extrapolated to target population.
In case healthy volunteers are not possible to enroll in single-
dose PK studies, then patients can be used in multi-dose PK
study. The relative bioavailability needs to be investigated for
individual administration site. The dose proportionality needs
to be evaluated in single or multiple doses with discussion of
clinical impact. Studies to be performed at several dose levels
and occasions. PK/PD relationship needs to be established and
evaluated.
Disease and patient characteristics: The age of patient
population, manifestation of disease at specified age, the type of
different treatments taken by the patients play important role
in selecting patients. It is advisable to perform comparative PK
study in mono-therapy to reduce variability. It is recommended
to select patient in better clinical condition, wherein the mAb can
be given in combination with other therapies.
PK characteristics of reference mAb: The designing of
anticancer mAb should be evaluated by considering multiple
dosing. Based on elimination mechanism (target mediated/non-
target mediated) of mAb, the PK studies should be designed. If it
is eliminated by both ways, comparable PK in healthy volunteers
should be performed for non-target mediated whereas the other
one should be performed in patient population as support data.
If receptor shedding is involved, then baseline comparability
studies should be performed. PK profile is not required for all
conditions specified for license mAb unless therapeutic category
is different.
Doses: The lowest therapeutic dose in patients should be
sufficient enough to identify difference in target mediated
clearance.
Route of administration: Subcutaneous routes should be
sufficient since this will characterize absorption and elimination.
Sampling: To be selected at first and last administration for
single dose study whereas for multiple dose study steady state
sampling is most preferred.
Design- A single-dose, cross-over with PK profile
characterization including late elimination phase is most
preferred. Parallel group design can be explored for longer
half-life and/or higher immunogenicity risk.
Regarding the route of administration, if two different routes
such as intravenous and subcutaneous are assigned to the
reference product, comparability PK study with subcutaneous
route alone would be sufficient with justification.
Acceptable range should be based on clinical judgment.
Parameters to be estimated as below:
Primary parameter should be AUC (0−inf) in single dose
study. Cmax, Tmax, volume of distribution and half-life and other
secondary parameters should be estimated and for subcutaneous
administration Cmax should be co-primary parameter.
As to multiple-dose study primary truncated AUC after first
until second administration AUC(0−t) and steady state AUC over
dosage interval, secondary- At steady state Cmax and Ctrough
should be primary parameters.
Pharmacodynamics (PD): For mAb PD studies, two types of
possibilities exist depending upon the availability of PD markers.
One in which PK and PD can be combined together if PDmarker
is available. In case PD markers are not available in vitro testing
should be performed.
To prove comparability dose concentration response
relationship or time response relationship should be established.
If fingerprinting approach is used by selecting non-surrogate
PD markers, then advice from regulatory agency is essential.
Clinical efficacy: The clinical efficacy studies are carried
out to establish that the biosimilar will not perform in a
manner that differs from the originator in clinically significant
manner. The principle is to demonstrate similar efficacy
compared to the reference medicinal product, not only patient
benefit which is already proven by the reference medicinal
product.
Study type: parallel design, random, double-blind adequately
powered comparative clinical studies using efficacy end-points in
absence of surrogate markers for efficacy.
Population: Patient for approved therapeutic indication of
reference product, in case of unapproved indication, justification
should be provided.
Design: Equivalence design expected, non-inferiority design
needs agency’s consent.
Endpoints: secondary endpoints of reference product are
sufficient for comparison with reference product.
Comparability margin:To be justified with some statistical and
clinical grounds by considering assay sensitivity.
The clinical studies in pediatric and elderly population are not
required. The inclusion of patients from non-European countries
may increase heterogeneity but if there are no known intrinsic
differences then it is possible to include mixed populations.
Clinical safety; Comparative safety data is expected to be
obtained before product authorization and the follow-up period
chosen needs to be justified. The adverse reactions are required
to be compared in terms of type, frequency and severity.
Immunogenicity and other risks need to be evaluated
and incorporated into the application dossier. Increased
immunogenicity as compared to reference product may lead to
products not considered to be truly biosimilar. Double-blind,
parallel analysis need to be done for measuring immunogenicity.
The analytical assays should have capability to detect reference
and proposed product antibodies and in addition all possible
antibody of proposed product. The antibody titers, cross-
reactivity, targeted epitopes and antigen neutralizing capacity are
required to be determined. The immunogenicity study duration
could be minimum 4 weeks in case of immune suppressive
agents are used or otherwise justified based on treatment
duration and removal of product from the circulation as well
as start of humoral immune response. Follow-up duration of 6
months during pre-authorization studies can be justified based
on immunogenicity profile and for chronic 1-year follow-up data
before marketing authorization application is essential. Further
follow-up data can be submitted post-authorization.
Extrapolation to other indications: Extrapolation (or extension
of the indication) is considered based on scientific justification of
quality (physico-chemical, structural and in vitro function test),
non-clinical (PK/PD) and clinical (safety/efficacy) comparability
in one indication.
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It might be challenging to extrapolate if the active substance
acts on several or multiple receptors with different clinical
outcomes in varied indications or hasmore than one active site or
the studied indication is irrelevant in terms of safety and efficacy
to the other indications.
Extrapolation of immunogenicity to other indications would
require justification (based on whether the therapy is one agent,
or the biological is added to another immunosuppressant.
Pharmacovigilance (PV) and Risk management plan (RMP):
Pharmacovigilance system details will be required and fully
described in marketing authorization applications. Suspected
adverse reactions will need appropriate tracing with brand name
and batch details of each product.
A Risk management plan, defining all known and potential
unknown risks needs to be monitored post market authorization
of the product. In addition, the safety studies of biosimilars
should cover all ongoing safety expectation of the reference
product (EMA, 2014a).
WHO
PK: Apart from EMA’s recommendation for using commercial
batch proposed product for clinical studies, WHO insists on PK
bridging studies providing PK profile comparison between two
different formulations, if non-commercialized product is used.
Single-dose pharmacokinetic data studies are sufficient in
general, however for mAbs, parallel group design with a larger
number of subjects are required (due to long half-life of mAbs,
single-dose, cross-over design may be inappropriate).
Key issues to be considered for mAb PK:
1. Healthy subject to be used due to higher sensitivity and
homogeneity in comparison to patient population
2. Sub-therapeutic dose to be considered due to ethical issues
3. Study in patient population could be mandatory due to safety
risks in healthy volunteers
4. It may be necessary to perform a PK study in a different
population considering different therapeutic indications
under development.
Antigen/receptor level, presence of target-mediated clearance
and/or receptor shedding of reference mAb has to be considered
for selection of the population to be studied.
Drug interactions and special population studies are not
required. For mAb biosimilar, it is not required to perform
PK study for each authorized indication of reference biological
product.
It is expected that comparative PK for mAbs will be
performed, considering mono-therapy to reduce variability
source. However comparative PK for both mono and
combination therapies have to be considered, if concomitant
therapy alters the PK of the mAb considered as a biosimilar.
Lowest recommended therapeutic dose needs to be used for
PK profiling. A higher dose may be required based on mAb
clearance characteristics.
To measure Cmax, sufficient sampling is expected at early
time points. For single-dose study, sampling has to be done till
last quantifiable concentration available. In multi-dose studies
sampling has to be done at first dose and at steady state
(expected to reach after 5 half-lives of mAb). However, there is
no clarity about type of 5 half-lives as PK half-life or biological
half-life.
Equivalence margin- For primary parameters 80-125% of
comparability margin is acceptable with justification.
PD: WHO recommends including PD markers as part of
clinical comparability exercise or confirmatory PD studies may
be performed in place of clinical safety or efficacy studies.
Clinical efficacy: Design: An equivalence trial design
is expected, with emphasis on the additional benefits for
extrapolation of indications.
The rest of the requirements for efficacy trials are equivalent
to those of the EMA.
Clinical safety: The comparative clinical safety requirement
is in line with EMA’s guideline; however, WHO presents a
multi-disciplinary approach for evaluation of immunogenicity
in mAbs. It covers risk assessment, risk-based immunogenicity
programme, comparative immunogenicity, assays and
mAb characterization and clinical immunogenicity
assessment.
Extrapolation to other indications: The extrapolation to
other indications can be considered subject to usage of a
sensitive clinical model for identification of differences, the
mechanism of action and/or applicable receptors are the
same, no new safety issues are expected when extrapolating
indications and equivalence design efficacy trials have been
performed.
Pharmacovigilance (PV) and Risk management plan (RMP):
WHO has advised to refer to ICH E2E for PV planning. In
general PV requirements are according to EMA’s expectations
(WHO-TRS, 2013).
USFDA
Clinical pharmacology: The PK and PD response assessment,
evaluation of residual uncertainty and analytical quality and
similarities are defined as three basic concepts for proposed
biosimilar development. To access potentially meaningful
difference between reference product and proposed biosimilar,
the inclusion of exposure and wherever possible exposure
response is essential in designing clinical PK/PD study. To
evaluate clinical pharmacology similarity, inclusion of PK
similarity and PD similarity (if applicable) are essential.
The PD response can be measured by using a single or a
composite biomarker.
It is expected to use material from the final manufacturing
process when performing a clinical pharmacology study.
Analytical and PK bridging study with the to-be-marketed
product will be necessary in case material is used from different
manufacturing processes.
The PK study design is recommended as cross-over for short
half-life product, having rapid PD onset and lower expected
immunogenicity. The PD assessment has to be performed using
multi-dose as against single dose of the PK study. The products
with long half-life, requiring repeated doses and chances of
increased immune responses will require parallel design studies.
Healthy subjects are expected if product can be administered
safely. However, patient population can be chosen if there are
ethical challenges or there are available PD markers in patients
(CBER, 2016).
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If drug-drug interaction and QT/QTc prolongation and
proarrhythmic potential studies are on-going for BLA holder,
then such studies would be essential for biosimilar manufacturer
as part of post-marketing approval (CBER, 2015).
It is expected to select the most sensitive dose for evaluation
of PK/PD similarity; based on the condition of the patient, the
dosing regimen can be decided.
The route of administration of the proposed product should
be the same as that of the reference product.
PK measurement: peak of concentration (Cmax), the total area
under the curve (AUC) for the reference product and proposed
biosimilar. For single dose study AUC to be calculated as AUC
(0−∞). For multiple dose study the total exposure to be calculated
as time concentration profile starting from zero to end of dosing
interval, at steady state, as AUC(0−tau).
The average equivalence statistical approach is expected to
compare clinical PK and PD similarity. To prove similarity the
expected calculated confidence interval limit is 80-125% if the
limit varies then justification is expected.
With reference to safety and immunogenicity, the data is
expected to be collected from clinical PK and PD study.
To evaluate clinical pharmacology similarity, FDA
recommends three types of bio-analytical assays as ligand
binding assays, concentration and binding assay, and PD assay
(CBER, 2016).
Extrapolation of indications: The proposed biosimilar product
can be licensed for additional indications, provided one
indication which is approved for the reference product was
the subject of biosimilarity studies and biosimilarity has been
proven. In addition, there needs to be consideration on
whether the clinical study performed scientifically justifies the
extrapolation. Apart from that, extrapolation of indications
in pediatric population is also possible, subject to scientific
justification.
The issues pertaining to MOA, PK and bio-distribution in
varied patient populations, immunogenicity, anticipated toxicity
differences and other relevant factors impacting efficacy should
be scientifically justified for the tested and all other extrapolated
indications (CBER, 2015).
Risk evaluation and mitigation strategy (REMS): REMS in line
with reference product are required to be submitted for proposed
biosimilar product (CBER, 2015).
Health Canada (HC)/BGTD
PK: The guidance document pertaining to information and
submission requirements for biosimilar biologic drugs indicates
PK requirements. It covers comparative PK study at low or sub-
therapeutic dosage in healthy subject or patients with appropriate
justifications. The design of the study needs to be decided,
based on set parameters. The equivalence margin for primary
parameters is expected as 90–125%.
The guidance document also states that comparative PK
criteria are to be defined based on the bioequivalence guidance
document: Conduct and analysis of comparative bioavailability
studies and comparative bioavailability standards: Formulations
used for systemic effects. However, the said guidance document
excludes applicability to subsequent entry biologics under scope.
PD: The guidance recommends characterizing the PK/PD
relationship if both studies are combined. Apart from
equivalence trial expectation, PD markers can be used, subject
to justification. For Canada, the calculations for PK studies
should follow those outlined for Bioequivalence studies as in the
Guidelines for Generic products. Acceptability of fingerprinting
approach is unclear with BGTD/Canada (Health-Canada/BGTD,
2016).
Clinical efficacy: Comparative clinical trials with equivalence
design are expected.
Clinical safety: Comparative clinical safety data (in terms
of adverse events including nature, severity and frequency) in
sufficient number of patients treated for suitable duration is
required as part of biosimilar application.
The BGTD has not defined immunogenicity requirements
in precise manner but accepts what is submitted provided it
is clearly laid out, well explained and justified. In general, the
expectations for comparative immunogenicity studies are aligned
with those of the WHO (Health-Canada/BGTD, 2012). The
follow-up duration for pre and post-authorization study is not
defined precisely however agency accepts what is submitted if the
plan is clearly laid out, well explained and justified.
Extrapolation to other indications: All indications can be
authorized based on one indication, subject to provision of
scientific rationale. However, if reference product’s specific
indication is not approved in Canada, then extrapolationmay not
be possible.
Pharmacovigilance (PV) and Risk management plan (RMP):
A Risk management plan needs to be prepared in consultation
with BGTD. In general, it covers requirements mentioned in the
EMA guideline and/or specific guidance document- Submission
of riskmanagement plans and follow-up commitments published
by Health Canada/BGTD (Health-Canada/BGTD, 2016).
BRICS-TM
Supplementary Table 8 indicates clinical requirements across
BRICS-TMmarkets.
ANVISA states comparative PK study along with PD can be
performed: however, there is no detailed information available
in Resolution RDC n◦ 55/2010. Comparative clinical studies
are required to be performed for safety and efficacy: however,
no further details have been provided. Extrapolation to other
indications is possible if product is registered through route of
development (and not through individual route of development),
however further detail is not defined. RDC n◦ 55/2010 does
not specifies detailed requirements on PV and RMP: however,
it refers to health legislation in effect (Anvisa, 2010). The
Resolution does not address the question of interchangeability
(Castaneda-Hernandez et al., 2014).
The biologic/mAb specific information is unavailable in the
Russian guideline (Russian-federation, 2014).
With respect to CDSCO, the PK study requirements are
aligned with those of the WHO. Comparative, parallel/cross-
over, healthy volunteers/patients, PD study is recommended
if at least one PD marker is linked with efficacy, which
is well characterized for the reference biologic. If PK study
can be done in patients and PD marker is not available,
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then PK and PD studies can be combined in a phase III
clinical trial. Confirmatory safety and efficacy are mandatory for
similar biologics. Equivalence, non-inferiority or comparability
phase III clinical trials can be conducted. Trial population
size can be reduced if a similar biologic is indicated for rare
diseases. Comparative safety study to be performed based on
adverse events, nature, severity and frequency. It is stated that
immunogenicity data should be obtained in PK/PD studies, if
a phase III trial is waived. No further details were available for
immunogenicity studies. Pre and post approval safety assessment
data are required. If safety and immunogenicity studies are
performed in more than 100 patients during pre-approval, phase
IV studies, patient numbers can be reduced accordingly. Based on
one specific clinical indication comparability data, extrapolation
can be done to other indications subject to the same mechanism
of action and receptors for all indications. New indications of
innovator can be approved by separate application. As per PV
plan, periodic safety update reports (PSURs) to be submitted
every 6 months for initial periods post approval of similar
biologics. Annual PSURs to be submitted for the subsequent 2
years (CDSCO, 2016).
The CFDA guideline about PK studies states healthy
volunteers or patients, design of the study, single/multiple dose
study and equivalence design with inclusion of elimination
characteristics, however details pertaining to similarity criteria,
dose selection sampling parameters are unavailable. Comparative
PD studies and PD biomarker usage are indicated with no
further detailed information. Comparative efficacy trial study
has to be performed, if clinical study material of proposed
product is different than the commercially available product.
PKPD requirements are aligned with the WHO. It states that
only common adverse reaction is to be compared and tested,
whereas information pertaining to unknown safety parameters is
not defined. Comparative clinical immunogenicity studies can be
conducted as part of PK, PD and/or efficacy trials and considered
for detecting antibodies linked to process-related impurities.
Extrapolation of indications can be considered based on scientific
justification. PV and RMP (safety and immunogenicity) have to
be submitted and evaluated as per national regulations (CFDA,
2014).
SAHPRA recommends PK study requirements similar to
EMA guideline on the clinical investigation of pharmacokinetics
of therapeutic proteins. It recommends combined PK/PD studies,
PD marker determination, selection of design and duration, all
based on justification. Comparative PD studies in a justified
population are acceptable. Comparative PK/PD studies may be
sufficient for clinical comparability if predefined conditions are
met. Comparable clinical efficacy trials should be conducted.
If a clinical comparability trial design is not feasible, other
designs should be explored. Safety and immunogenicity need
to be sufficiently characterized. Pre-registration of safety data
has to be performed in sufficient number of patients. The basic
principle for performing immunogenicity studies is in line with
EMA and WHO guidelines. If non-inferiority comparability
studies have been conducted for one indication, extrapolation
to other indications is possible. PV has to be based on MCC
guidelines and RMP should be presented or planned at the time
of marketing authorization application (MCC, 2014).
The TMMDA requirements are defined as in line with EMA’s
overarching biosimilar guideline for clinical studies (General-
Directorate-for-Pharmaceuticals-and-Pharmacy, 2017).
PK/PD, Clinical criteria are not defined; however, PV
information needs to be submitted in line with Mexican standard
(Cofepris, 2014). As indicated in regulations for biosimilars in
Latin America, Europe and India, review article by Castaneda
Hernandez, the Mexican regulations do not permit extrapolation
between indications (Castaneda-Hernandez et al., 2014).
DISCUSSION
The mAbs are complex biotherapeutic products requiring
stepwise and comprehensive development strategy considering
quality, non-clinical and clinical aspects to obtain biosimilar
approval by mature and emerging regulatory agencies. The
biosimilarity principles including development approach, basis
of biosimilarity, demonstration of biosimilarity with reference
product and type of applications is quite uniform across EMA,
WHOandUSFDA.However, with respect to BRICS-TM, some of
the parameters i.e. the simplified approach is yet to be clarified by
Brazil (ANVISA), China (CFDA), Russian federation andMexico
(COFEPRIS).
The parameters such as improved efficacy/safety,
comparability studies for post-approval changes and
interchangeability await clarifications from BRIC agencies.
The SAHPRA disallow interchangeability/switching whereas
TMMDA leaves the decisions with medical practitioners. The
guidance for pediatric research is at a very primitive stage across
BRICS-TM.
In general, mature agencies expect the reference product
to be sourced from their own territory having licensed the
product, based on full development data and provision of
bridging data for selection of non-reference product, for certain
comparability studies. It is evident that non-authorized reference
product selection criteria are missing for Russia and China
whereas Turkey does not require non-reference product for
characterization. The rest of BRICS-TM agencies allow selection
from ICH/own aligning countries while Mexico allows biosimilar
product to be used as reference product. Surprisingly, none of the
emerging market agencies talks about bridging data.
The comparative characterization exercise of the proposed
biosimilar in relation to the reference product specifies
physico-chemical studies (including detailed mAb structure,
immunological properties, biological activity, purity impurity
and contaminants, cell lines, quantity, specification),
manufacturing process, overages and compatibility as
detailed in the EMA guidelines. Although WHO has broadly
covered all four components of characterization, some of
the points i.e. amino acid sequencing, groups and bridges
determination, cytotoxicity, CDR and epitope evaluation,
multimers and aggregate characterization, contaminants control,
immortalization approach and need for experimental/in-process
stability data requirements are not specified. Most of the
NRAs in emerging markets have prepared similar biologic
guideline based on those of the WHO, hence presence/absence
of data requirements are similar to the ones of the WHO. The
requirements pertaining to manufacturing process, overages and
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compatibility characterization are not covered in the BRICS-TM
guidelines except a reference to WHO or ICH Q5A. The mAb
characterization requirement of USFDA is aligned with ICH
member states. In the view of the authors, it would be useful
for BGTD to revisit and define criteria for physico-chemical
characterization.
The comparative in vitro assays for binding signal
transduction and functional activity/viability studies are
specifically defined by the WHO, whereas reference guidelines of
BRICS-TMmarkets (except India), do not specify the need.
The repeat-dose toxicity, local tolerance, safety pharmacology,
reproductive toxicity, carcinogenicity in vivo toxicity studies
are aligned with EMA, WHO, TMMDA and SAHPRA. The
USFDA has considered ICH S6 (R1) whereas BGTD lacks
detailed information except non-requirement of in vivo studies,
if similarity is proven in previous steps. Russia and Mexico do
not specify detailed requirements whereas South Africa and India
are equivalent to the WHO. The immunogenicity toxicity studies
are essential for SAHPRA whereas EMA and WHO recommend
withdrawal of samples for PK/TK interpretation. The detailed
guidance for immunogenicity is awaited from other agencies.
The usage of commercial batch supply for clinical study
is the same for EMA and WHO, whereas WHO defines
the performance of bridging PK studies, if two different
formulations are used. The PK study is expected to be a
single dose, parallel design with late elimination stage by
both agencies for mAbs. The WHO expects 80–125% of
comparison margin for primary parameters. There are no
specific PK criteria defined for ANVISA, Russian federation
and COFEPRIS whereas CDSCO is aligned with WHO
and TMMDA (Turkey) with EMA. Canada advises to refer
the comparative BA studies and standards; however, BA
standards exclude applicability to subsequent entry biologics
under scope because BA guidance refers to oral and not
injectable preparations. Although the standards for analytical
results still apply to subsequent entry biologics. Comparative
clinical safety or efficacy could be enough, subject to PD
marker has been incorporated in PK/PD studies, with EMA,
WHO, BGTD, CDSCO, TMMDA, CFDA and SAHPRA. As
indicated earlier, Russia, and Mexico do not specify detailed PD
requirements.
Efficacy trials are required as parallel design, random, double-
blind, adequately powered with efficacy endpoint. Equivalence
trials are expected, and non-inferiority needs the consent of the
agencies. The efficacy trial design and type remain the same
for EMA, WHO, BGTD, TMMDA and CFDA. No detailed
information is available for ANVISA, Russian federation and
COFEPRIS. Confirmatory Phase III clinical safety and efficacy
are mandatory for India, whereas South Africa allows trial
design to be explored in case a comparative clinical trial is not
feasible. Comparative clinical safety data need to be obtained
before authorization and follow-up data to be submitted post
authorization across agencies stated in this article, except Brazil,
Russia, andMexico. The extrapolation of one indication to others
is acceptable based on scientific justification except with Mexico.
Interchangeability, switching and substitution of biosimilars is
not defined in BRIC whereas South Africa restricts, as per section
22F (Generics substitution) Act 101 of 1965. TMMDA leaves
interchangeability decision to practitioners. Pharmacovigilance
and RMP data need to be submitted across agencies.
To conclude, it is evident that regulatory frameworks for the
market authorization of biosimilars pose multiple challenges to
the companies in the emerging markets (Gautam, 2017). The
mAb specific development guidelines are yet to be published
by BRICS-TM agencies. The current Russian federation law
FZ-61 (December, 2014) has incorporated a definition for
biological/biosimilars, however the roles of the expertise are
to be determined by concerned federal authorities, resulting in
unfamiliar regulatory framework (Lozda, 2016), the regulatory
pathway would need clinical trial requirement based on
complexity of molecule (Priori, 2013). Mexico (COFEPRIS) is yet
to come up with detailed clarification for characterization, non-
clinical and clinical comparability criteria. Though there are gaps
in mAb biosimilar regulatory guidelines in emerging markets, we
believe that the agencies are working hard to align regulatory
norms in line with well-established agencies. The regulator
participates in multiple forums, exchanges knowledge and is
willing to upgrade. It would be advisable for the companies to
approach agencies in advance to obtain biosimilar development
advice so that hassle free authorization can be obtained. Further
to this, the authors are working on verifying gaps in biosimilar
development, regulatory evaluation procedures and approval
matrices from BRICS-TM agencies and will present in their
subsequent publications.
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